keyword
Keywords Metastatic hormone sensitive p...

Metastatic hormone sensitive prostate cancer

https://read.qxmd.com/read/38523897/real-world-prostate-specific-antigen-reduction-and-survival-outcomes-of-metastatic-hormone-sensitive-prostate-cancer-patients-treated-with-apalutamide-an-observational-retrospective-and-multicentre-study
#1
JOURNAL ARTICLE
Alicia López-Abad, Miguel Ramírez Backhaus, Gerardo Server Gómez, Enrique Cao Avellaneda, Cristóbal Moreno Alarcón, Pedro López Cubillana, Pablo Yago Giménez, Pedro de Pablos Rodríguez, María J Juan Fita, Miguel Á Climent Durán, Iris Guardiola Ruiz, Natalia Vidal Crespo, Miriam Artés Artés, Raúl Montoya Chinchilla, Juan Moreno Avilés, Pablo L Guzmán Martínez-Valls, Pedro Á López González
BACKGROUND: Metastatic hormone-sensitive prostate cancer (mHSPC) treatment has changed drastically during the last years with the emergence of androgen receptor-targeted agents (ARTAs). ARTA combined with androgen deprivation therapy has demonstrated better oncological and survival outcomes in these patients. However, the optimal choice among different ARTAs remains uncertain due to their analogous efficacy. OBJECTIVES: The objective of this study was to describe prostate-specific antigen (PSA) response and oncological outcomes of patients with mHSPC treated with apalutamide...
March 2024: Prostate International
https://read.qxmd.com/read/38523017/three-and-seven-month-prostate-specific-antigen-levels-as-prognostic-markers-for-overall-survival-in-metastatic-hormone-sensitive-prostate-cancer-results-from-swog-s1216-a-phase-3-randomized-trial-of-androgen-deprivation-plus-orteronel-or-bicalutamide
#2
JOURNAL ARTICLE
Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo, Andrea Harzstark, Channing J Paller, Saby George, Matthew R Zibelman, Heather H Cheng, Benjamin L Maughan, Jingsong Zhang, Russell K Pachynski, Alan H Bryce, Daniel W Lin, David I Quinn, Seth P Lerner, Ian M Thompson, Tanya B Dorff, Primo N Lara, Neeraj Agarwal
BACKGROUND: A robust decrease in prostate-specific antigen (PSA) in response to androgen deprivation therapy (ADT) has been evaluated as a prognostic factor in patients with metastatic hormone-sensitive prostate cancer (mHSPC) since 2006, but the treatment of mHSPC has since evolved to include intensified therapy. OBJECTIVE: We assessed the association of PSA levels at 3 (PSA-3mo) and 7 (PSA-7mo) mo with overall survival (OS) in patients with mHSPC treated with ADT combined with either bicalutamide or orteronel in the S1216 phase 3 clinical trial...
March 23, 2024: European Urology Oncology
https://read.qxmd.com/read/38500864/neoadjuvant-chemohormonal-therapy-before-radical-prostatectomy-in-high-risk-prostate-cancer-a-mini-review
#3
REVIEW
Junjie Fan, Zhangdong Jiang, Guojing Wang, Dalin He, Kaijie Wu
High-risk localized prostate cancer (PCa) has the potential of recurrence and progression to a lethal phenotype, and neoadjuvant therapy followed by radical prostatectomy (RP) may be an option for these patients. Docetaxel has been recently shown to be an effective chemotherapeutic agent for high-volume metastatic hormone-sensitive PCa and metastatic castration-resistant PCa, and these increased efficacy create the impetus to assess the potential role of preoperative docetaxel in high-risk localized PCa. In this mini-review, we found that neoadjuvant chemohormonal therapy (NCHT) may be an effective neoadjuvant regimen to improve oncological outcome of high-risk PCa...
2024: American Journal of Clinical and Experimental Urology
https://read.qxmd.com/read/38494380/systemic-and-tumor-directed-therapy-for-oligorecurrent-metastatic-prostate-cancer-saturn-primary-endpoint-results-from-a-phase-2-clinical-trial
#4
JOURNAL ARTICLE
John Nikitas, Matthew Rettig, John Shen, Robert Reiter, Alan Lee, Michael L Steinberg, Luca F Valle, Ankush Sachdeva, Tahmineh Romero, Jeremie Calais, Johannes Czernin, Nicholas G Nickols, Amar U Kishan
Nearly all men with metastatic hormone-sensitive prostate cancer treated with intermittent androgen deprivation therapy (ADT) experience recurrence within 6 mo of testosterone recovery. We conducted a single-arm phase 2 trial to evaluate whether addition of dual androgen receptor pathway inhibitors (ARPIs) and metastasis-directed stereotactic body radiotherapy (SBRT) to intermittent ADT improves recurrence rates for men with between one and five nonvisceral, extrapelvic metastases on prostate-specific membrane antigen positron emission tomography/computed tomography after prior radical prostatectomy...
March 16, 2024: European Urology
https://read.qxmd.com/read/38493067/feasibility-of-next-generation-sequencing-of-liquid-biopsy-circulating-tumor-dna-samples-and-tumor-tissue-from-patients-with-metastatic-prostate-cancer-in-a-real-world-clinical-setting-in-germany
#5
JOURNAL ARTICLE
Philipp Mandel, Benedikt Hoeh, Clara Humke, Claudia Doering, Mike Wenzel, Cristina Cano Garcia, Nina Fuhr, Florestan Koll, Anne Fassl, Derya Tilki, Thomas Steuber, Iris Faull, Jan Jeroch, Silvana Ebner, Christina Schmitt, Henning Reis, Jens Köllermann, Konstantinos D Kokkaliaris, Melanie C Demes, Felix K H Chun, Peter J Wild
BACKGROUND AND OBJECTIVE: With European Medicines Agency approval of PARP inhibitors in metastatic castration-resistant prostate cancer and ongoing trials in metastatic hormone-sensitive prostate cancer, detection of genetic alterations in BRCA1/2 and other homologous recombination repair genes has gained an important role. Our aim was to investigate the feasibility and comparability of comprehensive next-generation sequencing (NGS) of liquid biopsy (LB; circulating tumor DNA) and tumor tissue (TT) samples in a real-world clinical setting...
March 15, 2024: European Urology Focus
https://read.qxmd.com/read/38481910/remission-depth-in-metastatic-hormone-sensitive-prostate-cancer-is-associated-with-prognosis-in-patients-with-initial-prostate-specific-antigen-values-above-100-ng-ml
#6
JOURNAL ARTICLE
Takeshi Azuma, Akimasa Katsumata, Masato Kano, Koji Tsumura
INTRODUCTION: Recently, new drugs have caused a paradigm shift in the treatment of metastatic hormone-sensitive prostate cancer (HSPC). Meanwhile, research has identified several prognostic factors of metastatic HSPC. OBJECTIVE: The present study focused on remission depth in metastatic HSPC and evaluated its association with remission depth. METHOD: We analyzed 427 patients diagnosed with metastatic HSPC with serum initial prostate-specific antigen (PSA) > 100 ng/ml...
February 2024: Curēus
https://read.qxmd.com/read/38452035/a-phase-ii-study-of-rucaparib-monotherapy-in-nonmetastatic-hormone-sensitive-prostate-cancer-demonstrating-brcaness-genotype-roar
#7
JOURNAL ARTICLE
Kamal Kant Sahu, Haoran Li, Vinay Mathew Thomas, Mallory Benson, Ken Boucher, Sumati Gupta, Manish Kohli, Umang Swami, Neeraj Agarwal, Benjamin L Maughan
BACKGROUND: Both germline and somatic BReast CAncer gene (BRCA) mutations are poor prognostic markers in men with localized or metastatic prostate cancer. For instance, men with these mutations often are diagnosed with prostate cancer earlier and develop metastatic disease earlier compared with those who do not harbor similar mutations. Patients with germline alterations typically have more advanced disease and shorter overall survival (Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer...
March 7, 2024: Oncologist
https://read.qxmd.com/read/38447942/-role-of-bone-scan-index-bsi-in-the-prognosis-and-treatment-efficacy-in-castration-sensitive-prostate-cancer-patients-with-bone-metastasis
#8
JOURNAL ARTICLE
Kaho Deguchi, Takeshi Sasaki, Hiroyuki Oue, Takashi Okamoto, Momoko Kato, Shinya Kajiwara, Shinichiro Higashi, Satoru Masui, Kouhei Nishikawa, Takahiro Inoue
Bone is the most common metastatic site in prostate cancer (PCa). Although the extent of disease (EOD) grade is used for evaluating burden of bone metastasis, the accuracy of bone metastasis classification needs improvement. Bone scan index (BSI) was developed as a quantitative tool to enhance the interpretability and clinical relevance of the bone scan. This study aimed to explore the role of BSI using BONENAVI® software in determining the prognosis and treatment efficacy in castration-sensitive PCa (mCSPC) patients with bone metastasis...
February 2024: Hinyokika Kiyo. Acta Urologica Japonica
https://read.qxmd.com/read/38445371/optimal-systemic-therapy-in-men-with-low-volume-prostate-cancer
#9
JOURNAL ARTICLE
Akshat Saxena, Jack Andrews, Alan Haruo Bryce, Irbaz Bin Riaz
PURPOSE OF REVIEW: Low-volume prostate cancer is an established prognostic category of metastatic hormone-sensitive prostate cancer. However, the term is often loosely used to reflect the low burden of disease across different prostate cancer states. This review explores the definitions of low-volume prostate cancer, biology, and current evidence for treatment. We also explore future directions, including the impact of advanced imaging modalities, particularly prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans, on refining patient subgroups and treatment strategies for patients with low-volume prostate cancer...
March 6, 2024: Current Opinion in Urology
https://read.qxmd.com/read/38444678/lower-baseline-testosterone-level-is-related-to-earlier-development-of-castration-resistance-in-metastatic-prostate-cancer-a-multi-center-cohort-study
#10
JOURNAL ARTICLE
Ho Ming Chris Wong, Peter Ka-Fung Chiu, Ignacio Puche-Sanz, Zhao Xue, Dong-Ning Chen, Enrique Gomez-Gomez, Isabel Heidegger, Mona Kafka, Yong Wei, Shinichi Sakamoto, Anthony Chi Fai Ng
PURPOSE: In the era of concurrent combination therapy in metastatic hormone sensitive prostate cancer, the impact of the testosterone level before initiating androgen deprivation therapy on treatment outcome is still uncertain. We aimed to investigate its effect on time-to-castration-resistance in a metastatic hormone sensitive prostate cancer cohort. METHODS: This is a multi-center retrospective study of 5 databases from China, Japan, Austria and Spain including 258 metastatic hormone sensitive prostate cancer patients with androgen deprivation therapy initiated between 2002 and 2021...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38429210/development-and-independent-validation-of-a-prognostic-gene-expression-signature-based-on-rb1-pten-and-tp53-in-metastatic-hormone-sensitive-prostate-cancer-patients
#11
JOURNAL ARTICLE
Natalia Jiménez, Marta Garcia de Herreros, Òscar Reig, Mercedes Marín-Aguilera, Caterina Aversa, Laura Ferrer-Mileo, Samuel García-Esteve, Leonardo Rodríguez-Carunchio, Isabel Trias, Albert Font, Alejo Rodriguez-Vida, Miguel Ángel Climent, Sara Cros, Isabel Chirivella, Montserrat Domènech, Mariona Figols, Joan Carles, Cristina Suárez, Daniel Herrero Rivera, Enrique González-Billalabeitia, Claudia Cívico, Núria Sala-González, Vicenç Ruiz de Porras, Maria J Ribal, Aleix Prat, Begoña Mellado
BACKGROUND: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with an aggressive evolution and treatment resistance in castration-resistant prostate cancer (CRPC). OBJECTIVE: To study the clinical implications of TSG mRNA expression in mHSPC patients...
March 1, 2024: European Urology Oncology
https://read.qxmd.com/read/38424319/markers-of-bone-metabolism-and-overall-survival-in-men-with-bone-metastatic-hormone-sensitive-prostate-cancer-hspc-a-subset-analysis-of-swog-s1216-a-phase-iii-trial-of-androgen-deprivation-with-or-without-orteronel
#12
JOURNAL ARTICLE
Primo N Lara, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta van Loan, Maha Hussain, Shilpa Gupta, Jingsong Zhang, Mamta Parikh, Przemyslaw Twardowski, David I Quinn, Michael LeBlanc, Ian Thompson, Neeraj Agarwal
BACKGROUND: Circulating biomarkers of bone metabolism are significantly associated with overall survival (OS) in men with advanced prostate cancer. In the SWOG S1216 phase III trial, we showed that elevated bone biomarkers are significantly associated with an increased risk of death in hormone-sensitive prostate cancer (HSPC) regardless of the status of bone metastases, identifying three risk groups with differential OS outcomes based on bone biomarker status. Here we report the association of bone biomarkers with OS in men with HSPC and documented skeletal metastases as part of a planned subset analysis of S1216...
February 29, 2024: Prostate Cancer and Prostatic Diseases
https://read.qxmd.com/read/38418597/-palliative-surgery-for-metastatic-prostate-cancer
#13
REVIEW
Axel Heidenreich, Christian Bach, David Pfister
Androgen deprivation in combination with novel hormonal agents, docetaxel, or in combination with abiraterone/prednisone plus docetaxel or darolutamid plus docetaxel represent the standard therapeutic approach in metastatic hormone-sensitive prostate cancer (mHSPC). Patients with low-risk prostate cancer also benefit from additional radiation therapy or radical prostatectomy in terms of progression-free and overall survival. Despite favorable response rates, basically all patients will develop castration resistant prostate cancer (CRPC) within 2...
February 28, 2024: Urologie
https://read.qxmd.com/read/38398706/parp-inhibitors-in-metastatic-castration-resistant-prostate-cancer-unraveling-the-therapeutic-landscape
#14
REVIEW
Ashaar Al-Akhras, Chadi Hage Chehade, Arshit Narang, Umang Swami
The treatment landscape of metastatic prostate cancer (mPCa) is rapidly evolving with the recent approvals of poly-ADP ribose polymerase inhibitors (PARPis) as monotherapy or as part of combination therapy with androgen receptor pathway inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC). Already part of the therapeutic armamentarium in different types of advanced cancers, these molecules have shaped a new era in mPCa by targeting genomic pathways altered in these patients, leading to promising responses...
January 30, 2024: Life
https://read.qxmd.com/read/38388873/capivasertib-first-approval
#15
REVIEW
Matt Shirley
Capivasertib (Truqap™) is an orally available, small-molecule pan-AKT inhibitor being developed by AstraZeneca for the treatment of various cancers, including breast and prostate cancers. Capivasertib received its first approval, in the USA, in November 2023 for use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy...
February 23, 2024: Drugs
https://read.qxmd.com/read/38383277/risk-of-fractures-and-falls-in-men-with-advanced-or-metastatic-prostate-cancer-receiving-androgen-deprivation-therapy-and-treated-with-novel-androgen-receptor-signalling-inhibitors-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials
#16
REVIEW
Craig Jones, Struan Gray, Michael Brown, Janet Brown, Eugene McCloskey, Bhavan P Rai, Noel Clarke, Ashwin Sachdeva
CONTEXT: The addition of androgen receptor signalling inhibitors (ARSIs) to standard androgen deprivation therapy (ADT) has improved survival outcomes in patients with advanced prostate cancer (PCa). Advanced PCa patients have a higher incidence of osteoporosis, compounded by rapid bone density loss upon commencement of ADT resulting in an increased fracture risk. The effect of treatment intensification with ARSIs on fall and fracture risk is unclear. OBJECTIVE: To assess the risk of falls and fractures in men with PCa treated with ARSIs...
February 19, 2024: European Urology Oncology
https://read.qxmd.com/read/38375594/a-novel-hdac6-inhibitor-interferes-microtubule-dynamics-and-spindle-assembly-checkpoint-and-sensitizes-cisplatin-induced-apoptosis-in-castration-resistant-prostate-cancer
#17
JOURNAL ARTICLE
Pei-Chen Ye, Wohn-Jenn Leu, Tsung-Yu Yeh, Yu-Tung Hsu, Yi-Chin Lin, Zi-Yuan Wei, Yi-Chin Chen, Yi-Chang Chiang, Jui-Ling Hsu, She-Hung Chan, Lih-Ching Hsu, Ji-Wang Chern, Chao-Wu Yu, Jih-Hwa Guh
BACKGROUND: Metastatic castration-resistant prostate cancer (CRPC), the most refractory prostate cancer, inevitably progresses and becomes unresponsive to hormone therapy, revealing a pressing unmet need for this disease. Novel agents targeting HDAC6 and microtubule dynamics can be a potential anti-CRPC strategy. METHODS: Cell proliferation was examined in CRPC PC-3 and DU-145 cells using sulforhodamine B assay and anchorage-dependent colony formation assay. Flow cytometric analysis of propidium iodide staining was used to determine cell-cycle progression...
February 20, 2024: Prostate
https://read.qxmd.com/read/38375556/treatment-patterns-and-healthcare-resource-utilization-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-and-nonmetastatic-castration-resistant-prostate-cancer-in-china-a-real-world-observational-study
#18
JOURNAL ARTICLE
Yong Wang, Chunxiao Liu, Chuan Liu, Yongji Lu, Lu Ban, Yuanjie Niu
Aim: This study assessed the treatment patterns, healthcare resource utilization (HRU), costs, and annual prevalence and incidence of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) in China. Methods: A retrospective study was conducted using electronic medical records (EMR) of patients with prostate cancer from three tertiary-care hospitals in China between January 2014 and March 2021. Descriptive statistics were used to analyze study outcomes...
February 20, 2024: Journal of Medical Economics
https://read.qxmd.com/read/38362949/stereotactic-ablative-radiation-therapy-in-metastatic-prostate-cancer
#19
JOURNAL ARTICLE
Soha Bazyar, Heather Mannuel, Phuoc T Tran
PURPOSE OF REVIEW: The evolving role of stereotactic ablative radiation therapy (SABR) as metastasis-directed therapy (MDT) for oligometastatic prostate cancer (omPCa) will be discussed. RECENT FINDINGS: Oligometastatic disease (OMD) is an intermediate state between localized and wide-spread malignant disease. OMD has recently been spotlighted given the increasing demonstration of clinical benefit from local therapies despite presence of metastatic disease and allure of the curative potential of MDT in select cases...
February 15, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38353055/real-world-treatment-of-metastatic-hormone-sensitive-prostate-cancer-in-the-usa-europe-and-asia
#20
JOURNAL ARTICLE
Peter J Goebell, Rutika Raina, Stephanie Chen, Sanika Rege, Ruchit Shah, Jamie Partridge Grossman, A Reginald Waldeck
Aim: To characterize real-world patients with metastatic hormone-sensitive prostate cancer (mHSPC) and treating physicians and evaluate treatment trends and baseline concordance versus guidelines internationally. Materials & methods: Retrospective, cross-sectional data from the Ipsos Global Oncology Monitor database 2018-2020 were used for descriptive analysis of mHSPC patients, treating physicians and treatment utilization. Results: Among the 6198 mHSPC patients from five countries, the most common treatment was either androgen deprivation therapy (ADT) monotherapy or first-generation androgen receptor inhibitor + ADT...
February 14, 2024: Future Oncology
keyword
keyword
161291
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.